Prima BioMed (IMMP) Competitors $1.65 +0.01 (+0.61%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.69 +0.04 (+2.18%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMP vs. NAGE, DYN, CDTX, COLL, BGM, PHVS, NRIX, PRAX, AKBA, and SYREShould you be buying Prima BioMed stock or one of its competitors? The main competitors of Prima BioMed include Niagen Bioscience (NAGE), Dyne Therapeutics (DYN), Cidara Therapeutics (CDTX), Collegium Pharmaceutical (COLL), BGM Group (BGM), Pharvaris (PHVS), Nurix Therapeutics (NRIX), Praxis Precision Medicines (PRAX), Akebia Therapeutics (AKBA), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry. Prima BioMed vs. Its Competitors Niagen Bioscience Dyne Therapeutics Cidara Therapeutics Collegium Pharmaceutical BGM Group Pharvaris Nurix Therapeutics Praxis Precision Medicines Akebia Therapeutics Spyre Therapeutics Prima BioMed (NASDAQ:IMMP) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability. Does the media refer more to IMMP or NAGE? In the previous week, Niagen Bioscience had 3 more articles in the media than Prima BioMed. MarketBeat recorded 4 mentions for Niagen Bioscience and 1 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.87 beat Niagen Bioscience's score of 0.74 indicating that Prima BioMed is being referred to more favorably in the media. Company Overall Sentiment Prima BioMed Very Positive Niagen Bioscience Positive Which has more risk & volatility, IMMP or NAGE? Prima BioMed has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Is IMMP or NAGE more profitable? Niagen Bioscience has a net margin of 13.07% compared to Prima BioMed's net margin of 0.00%. Niagen Bioscience's return on equity of 19.06% beat Prima BioMed's return on equity.Company Net Margins Return on Equity Return on Assets Prima BioMedN/A N/A N/A Niagen Bioscience 13.07%19.06%12.20% Which has better earnings & valuation, IMMP or NAGE? Niagen Bioscience has higher revenue and earnings than Prima BioMed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrima BioMed$5.14M46.88-$28.01MN/AN/ANiagen Bioscience$99.60M8.94$8.55M$0.1766.47 Do institutionals & insiders hold more shares of IMMP or NAGE? 2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 3.1% of Prima BioMed shares are held by company insiders. Comparatively, 9.4% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer IMMP or NAGE? Prima BioMed currently has a consensus target price of $7.00, suggesting a potential upside of 324.24%. Niagen Bioscience has a consensus target price of $19.50, suggesting a potential upside of 72.57%. Given Prima BioMed's higher probable upside, research analysts clearly believe Prima BioMed is more favorable than Niagen Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Niagen Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryNiagen Bioscience beats Prima BioMed on 10 of the 13 factors compared between the two stocks. Get Prima BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMP vs. The Competition Export to ExcelMetricPrima BioMedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$240.96M$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.06%4.01%P/E RatioN/A20.8528.2320.27Price / Sales46.88298.79434.20100.92Price / CashN/A42.1137.1257.67Price / Book1.577.638.045.49Net Income-$28.01M-$55.05M$3.19B$250.45M7 Day Performance-3.51%8.43%3.62%4.78%1 Month Performance-5.17%8.14%5.98%9.58%1 Year Performance-28.57%1.62%29.39%16.41% Prima BioMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMPPrima BioMed1.5086 of 5 stars$1.65+0.6%$7.00+324.2%-28.6%$240.96M$5.14M0.002,021Positive NewsNAGENiagen Bioscience1.3498 of 5 stars$12.44-2.1%$19.50+56.8%+333.0%$1.00B$99.60M141.22120DYNDyne Therapeutics3.4007 of 5 stars$8.18-6.6%$41.13+402.8%-79.2%$995.72MN/A-2.28100Analyst ForecastHigh Trading VolumeCDTXCidara Therapeutics4.1382 of 5 stars$48.30-1.0%$57.14+18.3%+340.2%$983.59M$1.27M-1.6490Positive NewsAnalyst ForecastGap UpHigh Trading VolumeCOLLCollegium Pharmaceutical4.2136 of 5 stars$30.90+1.8%$43.75+41.6%+2.3%$975.20M$631.45M25.33210Buyback AnnouncementBGMBGM GroupN/A$10.00-0.3%N/AN/A$975.14M$25.10M0.00298PHVSPharvaris1.4054 of 5 stars$18.00-3.2%$36.20+101.1%+33.8%$972.60MN/A0.0030News CoverageNRIXNurix Therapeutics1.5713 of 5 stars$12.36-2.9%$30.18+144.1%-47.8%$970.48M$54.55M-4.41300Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap DownPRAXPraxis Precision Medicines2.4409 of 5 stars$46.68-1.2%$92.11+97.3%-0.7%$962.64M$8.55M0.00110Analyst ForecastAKBAAkebia Therapeutics3.5782 of 5 stars$3.63+0.3%$6.75+86.0%+211.9%$950.74M$160.18M-17.28430SYRESpyre Therapeutics2.2495 of 5 stars$15.30-2.9%$53.40+249.0%-47.1%$949.94M$890K-4.0673Positive News Related Companies and Tools Related Companies Niagen Bioscience Alternatives Dyne Therapeutics Alternatives Cidara Therapeutics Alternatives Collegium Pharmaceutical Alternatives BGM Group Alternatives Pharvaris Alternatives Nurix Therapeutics Alternatives Praxis Precision Medicines Alternatives Akebia Therapeutics Alternatives Spyre Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMP) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prima BioMed Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Prima BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
